{
  "docId": "019de073-c7d4-73ef-8fef-22f9b5017668",
  "docSlug": "c95aa30aee69a466f8f903e1480a3b33",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 32 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 32,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The chart displays a longitudinal study of FXN concentration across different dose groups (Placebo, 25mg, 50mg, 100mg) at Baseline, Day 4/7, and Day 13.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-c7d4-73ef-8fef-22f9b5017668/12",
  "deckHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668",
  "deckJsonHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668.json",
  "deckAnchorHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "chart",
      "text": "FXN* Levels By Dose Group (Buccal Cells)",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16a4a36e-8fdd-4988-bb1c-e5746db52f0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "Benchmarking Clinical Relevance: FXN levels in buccal cells and blood correlate with neurological function; FA patients produce 20-40% of normal levels; Heterozygous carriers have ~50% of normal levels.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97a242dd-e850-4d73-8d3a-3e40805f95c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "list",
      "text": "Comparison to Healthy Controls: Measured in 8 healthy controls; Patients in Cohorts 2 & 3 achieved >60% of healthy control levels.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b923c37f-c4bc-4350-aefc-20adae1c6f47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "*FXN levels measured via detection of peptide derived from mature FXN; Data on file; Data represent median and 25th and 75th percentiles...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3b9b199-4598-4518-b43d-6b5dae9e7f89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "title",
      "text": "Achieved median FXN levels that were >60% of the median FXN levels observed in healthy controls",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf55e603-6032-4440-ae92-9af698eb1c0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Data Compare Favorably to FXN Levels Expected in Heterozygous Carriers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13ea943f-259b-4b7b-b812-ff038694e0b8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 8,
      "beatId": "8bf4cfad-4916-4c9e-af27-192a9a042ffa",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck highlights positive clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 8,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "d0d0eba8-b767-4a62-beb5-07c937ed50af",
      "evidence": "The deck presents positive clinical trial results",
      "position": 2,
      "objective": "Demonstrate the efficacy of CTI-1601",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}